Tki Emea company information, Employees & Contact Information

Non-invasive identification of TKI-resistant NSCLC: a multi-model AI approach for predicting EGFR/TP53 co-mutations BMC Pulmonary Medicine

US tech firm TKI expands to Cyprus eKathimerini.com

Taletrectinib Demonstrates Durable Responses in TKI-Naive and -Pretreated ROS1+ NSCLC OncLive

AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma ScienceDirect.com

Cyprus’ Hybrid ConsulTech Merges with US’ TKI in AI Move The National Herald

Exploring Factors Supporting TKI Discontinuation in Patients With Ph+ ALL Targeted Oncology

US AI provider TKI expands to Cyprus to serve Europe, Middle East, and Africa Philenews

Clonal driver neoantigen loss under EGFR TKI and immune selection pressures Nature

Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC OncLive

Invest Cyprus welcomes US-based TKI following merger with Hybrid ConsulTech Cyprus Mail

US-based TKI and Cyprus-based Hybrid ConsulTech to operate under the unified TKI brand cbn.com.cy

Zanzalintinib/Atezolizumab Improves CRC Survival, Expands TKI's Role in Solid Tumors Targeted Oncology

Global Compliant Exchange MctynFcbfy Welcomes Powerful GlobeNewswire

Ivonescimab Plus Chemo After Third-Generation TKI Generates Improved PFS in EGFR-Mutated NSCLC OncLive

TKI and Hybrid ConsulTech merge under unified brand, establish EMEA in Cyprus Cyprus Mail

AlphaFold AI Sets Stage for Future Approaches in Cancer Targeted Oncology

How should we interpret conclusions of TKI-stopping studies - Leukemia Nature

Zidesamtinib Produces Durable Responses in TKI-Pretreated, ROS1+ NSCLC OncLive

Zidesamtinib Data Align With Clinical Expectations in Pretreated ROS1+ Advanced NSCLC OncLive

TKI Advances and Patient-Centered Decision-Making Guide the Path Toward Functional Cures in CML OncLive

Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR -Mutant NSCLC The ASCO Post

IFNγ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma | Cell Death & Disease Nature

Targeting the SYVN1-EGFR axis: a breakthrough strategy for TKI-resistant NSCLC Nature

Conflict Management and AI HR Daily Advisor

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers Nature

Sitravatinib May be the ‘Missing TKI’ for Dedifferentiated Liposarcoma CancerNetwork

Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 - Leukemia Nature

Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC Nature

Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia Wiley Online Library

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC Medical Xpress

Comparing Choices for IO/TKI Combinations in Advanced RCC Targeted Oncology

Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation Nature

Combining Radiotherapy With a TKI Extends Survival in NSCLC Medscape

Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion Nature

OTX-TKI shows durable results in treatment of neovascular AMD Healio

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants Nature

Consensus on the lung cancer management after third-generation EGFR-TKI resistance The Lancet

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC | Scientific Reports Nature

Targeting HER3 to overcome EGFR TKI resistance in NSCLC Frontiers

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers Genetic Engineering and Biotechnology News

IO-TKI Combinations Have Potential as Preferred First-line mRCC Therapy The American Journal of Managed Care® (AJMC®)

Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review Frontiers

FGFR-TKI resistance in cancer: current status and perspectives Journal of Hematology & Oncology

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective Nature

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer Journal of Hematology & Oncology

Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China The AI Journal

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison Nature

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation Nature

TKI promotes living and working in climate-neutral building and infrastructure TNO

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC Nature

Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway Nature

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells Nature